Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4361370 | 0.93 | ALK (0.50) | JAK2ALKALDH1A1KDM4EKMT2A | |
| SCHEMBL4357170 | 0.89 | ALK (0.40) | JAK2ALKALDH1A1TSHRKMT2A | |
| Trifluoroacetic Acid SCHEMBL4352702 | 0.89 | ALK (0.46) | JAK2ALKALDH1A1KDM4ETSHR | |
| SCHEMBL13634103 | 0.87 | ALK (0.41) | JAK2ALKALDH1A1TSHRKMT2A | |
| SCHEMBL4362001 | 0.86 | ALK (0.42) | JAK2ALKALDH1A1KDM4ETSHR | |
| Trifluoroacetic Acid SCHEMBL1075811 | 0.85 | ALK (0.37) | JAK2ALKALDH1A1TSHRTHRB | |
| SCHEMBL13632936 | 0.83 | ALK (0.40) | JAK2ALK | |
| Trifluoroacetic Acid SCHEMBL4354180 | 0.82 | ALK (0.39) | JAK2ALKALDH1A1KDM4ETSHR | |
| SCHEMBL4359814 | 0.82 | ALK (0.49) | JAK2ALK | |
| SCHEMBL4370120 | 0.82 | ALK (0.39) | JAK2ALKALDH1A1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | JAK2 1/4885ALK 3/4885ALDH1A1 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.